Letter: value of fluorodeoxyglucose positron emission tomography in women with breast cancer ( Br J Surg  2005; 92: 1363-1367) by Hayanga, Awori J.
252 Correspondence
Authors’ reply: Treatment of
loculated lactational breast abscess
with a vacuum biopsy system
(Br J Surg 2005; 92: 1225–1226)
Sir
Thrush and Dixon describe an alterna-
tive method for aspirating viscous pus
from breast abscesses. This is similar
to the method we use normally, before
resorting to the use of a mammotome
for abscesses that do not resolve. We
would note, however, that the initial
injection of a volume of local anaes-
thetic into an abscess cavity can be very
painful.
One of the reasons we have a lower
threshold to perform a mammotome
aspiration of the pus in our series as well
as the many which we have performed
since, is the fact that we rarely need
to perform any more aspirations. Once
the mammotome aspiration has been
done, we see the patient once more
to check that the abscess is resolving
and then give an open appointment.
This has the advantage of fewer visits
to the clinic at an important time for
mother and baby. Another advantage,
also alluded to by Thrush and Dixon,
is the biopsy. We once missed early
diagnosis of a cancer in what seemed
to be a lactating abscess in a young
woman whose infection appeared to be
responding to repeated aspirations.
M. Shere
The Breast Care Centre, Frenchay
Hospital, Bristol BS16 1LE, UK
DOI: 10.1002/bjs.5313
Letter: Value of fluorodeoxyglucose
positron emission tomography in
women with breast cancer
(Br J Surg 2005; 92: 1363–1367)
Sir
Landheer and colleagues failed to add
any substantial data to the existing body
of information within the literature on
the topic. Like many previously pub-
lished studies, theirs was underpow-
ered (n = 42) to arrive at any conclu-
sive diagnostic statistics and they must
surely be aware that FDG-PET scan-
ning is not an adequate screening tool1.
Furthermore, its accuracy in detect-
ing metastatic tumour in the axilla was
only 70 per cent, much lower than that
of ultrasound2. Tumours below 1 cm
in diameter are beyond the resolution
capabilities of FDG-PET and so will
not be visualized, and it is too expensive
to use routinely. Some tumours have
chemoresistant clones and lack the spe-
cific glucose transport proteins to allow
them to exhibit FDG avidity, and are
thus invisible to FDG-PET2.
Mention is warranted too of the
newer positron emitting labels such
as FLT (fluoro-L-thymidine) that may
be more tumour-specific and thus
more sensitive2. The authors should
be cautioned against confusing the
limitations of FDG kinetics with those
of PET.
Finally, they failed to mention the
most topical application of FDG-PET
research, namely the monitoring of
response to neoadjuvant chemother-
apy for breast cancer. Functional dig-
ital imaging has effectively questioned
the conventional reliance on size as
the only criterion for monitoring
response to therapy. Because there
is growing evidence that changes in
tumour metabolism precede changes
in morphology3, PET CT with novel
tracers may (with improvements in
spatial resolution, iterative reconstruc-
tion algorithms and correction for
partial volume) evolve into a useful
tool in staging of breast cancer and
assessing response to chemotherapy.
This would be of importance to non-
responders who may then be detected
early, have their regimens altered and
their exposure to ineffective, toxic drugs
reduced.
A. J. Hayanga
Department of General Surgery, 1500 E.
Med Center Drive, Taubman Center,
University of Michigan Health Systems,
Ann Arbor, MI 48109, USA
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Authors’ reply: Value of
fluorodeoxyglucose positron
emission tomography in women
with breast cancer (Br J Surg 2005;
92: 1363–1367)
Sir
Being well aware of the intrinsic limi-
tations of FDG-PET in breast cancer,
we do not advocate its use as a screen-
ing technique. The aim of our study
was to evaluate the role of FDG-PET
in the detection of distant metastases in
women with primary or recurrent breast
cancer. As the study was intended as a
pilot, we are aware that it was under-
powered to draw definite conclusions.
However, we do not share the opinion of
Hayanga that FDG-PET is too expen-
sive to use routinely; it is not a question
of cost, but of cost-effectiveness. This
requires careful assessment of the new
technology, including optimal patient
selection and rigorous evaluation of all
effects (medical, social and economic).
A recent Canadian meta-analysis con-
cluded that the use of a PET manage-
ment strategy for the staging of breast
cancer is expected to remain economi-
cally viable in Canada1.
The statement that detection of
tumours below 1 cm in diameter is
beyond the resolution capabilities of
FDG-PET is not completely correct.
Metabolic activity rather than size
determines FDG-PET positivity. Very
large (usually benign or very well-
differentiated cancers) may be PET-
negative, while metabolically active
lesions of just a few mm may be
depicted by FDG-PET. We do not
share the view of Hayanga on the use
of other tracers like FLT. The fact
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